Meeting
2023 ASCO Annual Meeting
Phase I/II trial of durvalumab plus tremelimumab and stereotactic body radiotherapy for metastatic head and neck carcinoma: Final results.
Authors
Houda Bahig
Centre Hospitalier de l'Université de Montréal, Montreal, QC, Canada
Houda Bahig , Francine Aubin , Phuc Felix Nguyen-Tan , Denis Soulieres , Brock John Debenham , Danielle Charpentier , David A. Palma , Eric Winquist , Rahima Jamal , Khalil Sultanem , Olivier Ballivy , Edith Filion , Tyler Pittman , Manjula Maganti , Philip Wong
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Head and Neck Cancer
Track
Head and Neck Cancer
Sub Track
Advanced/Metastatic Disease
Clinical Trial Registration Number
NCT03283605
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 6050)
DOI
10.1200/JCO.2023.41.16_suppl.6050
Abstract #
6050
Poster Bd #
42
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Genitourinary Cancers Symposium
Safety lead-in of phase II SBRT and durvalumab with or without tremelimumab for unresectable and cisplatin-ineligible, locally advanced or metastatic bladder cancer.
First Author: Palak Kundu
Poster
2022 ASCO Annual Meeting
Preoperative durvalumab (D) with or without tremelimumab (T) for resectable head and neck squamous cell carcinoma (HNSCC): Updated results with high dimensional profiling of circulating immune cells.
First Author: Chang Gon Kim
Poster
2021 ASCO Annual Meeting
Phase II trial of combined durvalumab plus tremelimumab with proton therapy to boost the abscopal effect for recurrent or metastatic head and neck squamous cell carcinoma.
First Author: Hana Kim
Poster
2020 Gastrointestinal Cancers Symposium
A pilot study of durvalumab/tremelimumab (durva/treme) and radiation (XRT) for metastatic biliary tract cancer (mBTC): Preliminary safety and efficacy.
First Author: Theodore S. Hong